The neurochemistry of language and the neuropharmacology of aphasia are two domains of cognitive neuroscience still in their infancy. In this article we review what is known about these two domains, especially with regard to treating aphasia with drugs. Selected neurotransmitters can improve language function in certain patients with aphasia. We discuss which neurotransmitters work for which language functions in which patients, and why.
cerebral dominance and the neuroanatomy of language. This is followed by a summary of the neural aspects of cerebral injury and recovery. We then discuss neurochemistry as it applies to language, and the possibilities for drug therapy as an alternative/complementary approach for the treatment of aphasia.
NEUROANATOMY OF APHASIA
The concepts of cerebral lateralization and localization of function are relatively modern concepts in the history of cognitive neuroscience. Goodglass 2 provided a thorough review of the early history of this work as far back as Hippocrates in the fifth century BC; however, currently accepted theories began in 1861 with Paul Broca. In that year Broca described language disorders originating from lesions of the left hemispheric, but not right, cerebral hemisphere. He determined that lesions in the inferior portion of the left third frontal convolution, now known as Broca's area, were the source for loss of speech. Broca called these language deficits ''aphemia'' but a few years later Trousseau coined the term ''aphasia.'' Thus began modern attempts to lateralize and localize language functions in the brain. In 1874, Wernicke described lesions in the posterior first temporal gyrus producing a ''sensory'' aphasia with impaired auditory comprehension. This neuroatomical site is now referred to as Wernicke's area. Four years later, Lichtheim described lesions in the pathways beneath the angular and supramarginal gyri that connect Broca's area and Wernicke's area that resulted in a language syndrome he called ''conduction aphasia. '' 2 During the 1860s and 1870s Jackson wrote about the links between propositional language and underlying intellectual capacity, expanding the concept of brain-language relations from one that was strictly mechanistic to one that incorporated language within a larger cognitive sphere. Another major shift in thinking came with the work of Alajouanine at the turn of the last century. He initiated the first crossdisciplinary neurolinguistic collaborative effort, interconnecting the work of linguists, psychologists, and neurologists. As the 19th century turned into the 20th, two major schools of thought prevailed with regard to brainlanguage relations, one focusing on what has come to be called ''localizationism'' (i.e., components of language can be highly localized in the brain), the other, ''holism'' (i.e., language elements are widely distributed throughout the brain and are enveloped within networks for other cognitive domains). As we discuss later, each of these schools of thought is relevant to pharmacotherapy for aphasia.
Throughout the first half of the last century, localizationists and holists battled. In 1965 Geschwind 3 offered a third approach, still popular today, called ''connectionism.'' Connectionism argues that the connections among regional nodes responsible for language function are as important as the regional nodes themselves. At about the same time, he introduced the present-day dichotomy of fluent and nonfluent categories to describe two major subtypes of aphasia. Geschwind and Levitsky in 1968 published seminal work on cerebral dominance by showing that the planum temporale, ''the cortex buried in the sylvian fissure posterior to the primary auditory cortex, is larger in the hemisphere dedicated to language.'' 4 The planum temporale is considered to be part of Wernicke's area. Studies of cerebral dominance indicate that 98% of right-handers have language dominance in the left hemisphere. Of left handers, 70% are considered to have language dominance in the left hemisphere and 30% in the right hemisphere. In rare cases a right hemispheric lesion in right-handed individuals produces a ''crossed aphasia.'' Good evidence exists that subcortical lesions can cause aphasia in patterns distinct from the classical cortical Broca's and Wernicke's aphasias. In 1982 Naeser and associates 5 described aphasia caused by subcortical lesions that involved the internal capsule, putamen, and adjacent periventricular white matter. Some lesions extended to include small cortical areas but not Broca's area, Wernicke's area, the angular gyrus, or supramarginal gyrus. Three patterns of aphasia emerged from this study. The first pattern involved an anterior lesion with superior extension into the white matter that produced slow, agrammatical, dysarthric output with good comprehension and right hemiparesis. The second pattern was associated with a posterior lesion with white matter extension involving the auditory radiations in the temporal isthmus, resulting in fluent output, poor comprehension, and right hemiparesis. The third pattern involved both anterior and posterior extensions associated with global aphasia and right hemiparesis.
Associated clinical findings help localize and categorize the various aphasias. Lesions in frontal areas adjacent to Broca's area can produce mutism or dysarthria, as well as aphasia. 6 The supplemental motor area (SMA) in the frontal lobe has been found to be involved in the initiation of language output. 2 Lesions of the left SMA can cause transcortical motor aphasia. This area has also been associated with ability to count silently, verbal recitation of overlearned material, and initiation of motor speech output. (Note that the SMA acts in conjunction with the anterior cingulate region to link with the midbrain, connecting through the striatum by way of the subcallosal fasiculus.) Lesions involving the subcallosal fasciculus within periventricular white matter have been shown to produce severe nonfluent aphasia. 7 Ongoing research continues to evaluate and correlate language function and lesion localization. There are many low-tech and high-tech modalities available to assist in this endeavor. Brain damage leading to a specific deficit is examined clinically and pathologically to correlate clinicoanatomical patterns. Intraoperative electrical stimulation can be applied directly to neurons to evaluate their function. Intravascular infusions of amobarbital (the ''Wada Test'') have been used to release inhibitory effects of focal groups of neurons. Current techniques also include physiological studies with electroencephalograms, metabolic and blood flow studies with positron emission tomography (PET) and single photon emission computed tomography, and structural imaging with computed tomography and magnetic resonance imaging. The field of cognitive neuroscience has emerged at the confluence of research by neurologists, neuropsychologists, linguists, speech-language pathologists, and neuroimaging specialists who continue their research to further refine functional-anatomical correlations. As we discuss later, the neurochemical anatomy of language overlaps the neuroanatomy of language, providing the scientific rationale for pharmacotherapy of language disorders in aphasia.
RECOVERY OF FUNCTION:
PATTERNS, MECHANISMS, AND NEURAL ASPECTS Lesion localization is important for accurate diagnosis of aphasia, which, in turn, aids in prognosis for recovery. At the same time, the study of spontaneous clinical recovery helps us to understand brain mechanisms underlying aphasia. Many factors have been shown to influence a more favorable outcome following onset of aphasia. These factors include milder aphasia and younger age at onset; form of aphasia, with comprehension deficits improving more than output deficits; higher premorbid educational level; left handedness; right handedness with left-handed first-degree relatives; traumatic brain injury instead of ischemic stroke as etiology; smaller lesion size; and absence of neurobehavioral comorbidities (amnesia, dementia, inattention, agnosia, apraxia). Also influencing outcomes are the individual's degree of drive and motivation and social milieu, as well as time of administration of speech and language therapy (the earlier the better likelihood of positive response) and appropriateness of the type of therapy.
Over the years attempts have been made to explain recovery of language function following onset of aphasia. Two postulates are (1) that the right hemisphere assumes language functions, and (2) that there is greater activation of the remaining cells of the left hemisphere. Apparently, both mechanisms occur. One study, 8 for example, used PET scanning, which evaluates regional cerebral blood flow and glucose metabolism, both of which are markers of neuronal activity. Recovery in six patients with Wernicke's aphasia was evaluated using repetition of pseudowords (a nonlexical phonological task) and verb generation (a lexical semantic task). Homotopic areas of the right hemisphere did show activation, indicated by increased blood flow and increased glucose metabolism. In addition, there was increased activation of the left inferior frontal area corresponding to Broca's area and increased activation of the left lateral prefrontal cortex.
By understanding what happens at the cellular, biochemical level when the brain is damaged, clinicians and researchers have bases for developing new approaches to therapy, in particular, pharmacological approaches. Various types of injury to the brain can lead to aphasia. The most common cause is ischemic stroke involving the left middle cerebral artery, but, traumatic brain injury, tumors, focal infections, and focal lobar degeneration of the frontotemporal areas can also lead to aphasia. These neuropathological entities all have in common disruption of the blood-brain barrier. This barrier consists of highly specialized capillary endothelial cells acting to prevent the passage of substances dissolved in or carried by the blood. Equally important is the barrier's function as a selective transport system to allow the passage of substrates such as glucose, steroid hormones, and precursors to the various neurotransmitters (chemicals that allow intercellular communication). Breaching this barrier unleashes a cascade of biochemical events leading to brain damage. 9 These events are swift and complex and are the subject of intense research.
Ischemia causes release of excitotoxic neurotransmitters including glutamate directly from neurons and the supporting glial cells. Binding to specialized receptors, NMDA (N-methly D-aspartate), AMPA (a-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid), and kainate cause release of calcium, leading to an influx into the brain of sodium, resulting in increased intracellular water, neuronal swelling, and membrane disruption. Necrosis or cell death ensues that is maximum at the core and less in the surrounding areas, called the penumbra. If excess sugar, or hyperglycemia, is also present, there is an increase in lactic acid enlarging the core area of damage, decreasing the survival rate of penumbral cells, and resulting in a less favorable clinical outcome. 10 Free radicals (hydrogen, oxygen, and iron particles with extra electrons) are also released at the time of initial injury, leading to destruction of cell membrane fatty acids via lipid peroxidation. The cell literally falls apart. As the neurons and glial cells die they activate macrophage scavenger cells. The destructive cascade continues, resulting in not only immediate cell death but also secondary degeneration over the next few weeks to months. Surrounding cells that do survive may remain weak and vulnerable permanently. 10 An understanding of these mechanisms can lead to therapeutic intervention to stop the destructive cascade.
In some cases notable spontaneous recovery does occur and there are several neural mechanisms underlying this recovery. Enhancing these mechanisms of spontaneous recovery is another avenue for therapeutic intervention. Mechanisms of recovery include vicariance (one cerebral area takes over for another), redundancy (duplicate neural back-up systems are released from inhibition), functional substitution (a part of the brain not usually involved in a task takes over that task), and release from diaschisis (distant areas initially suppressed recover function). On a cellular level these behavioral descriptions may involve regeneration of damaged cells and sprouting from nondamaged collateral cells. 10 Neurotrophic factors, such as nerve growth factor, are proteins that stimulate growth and guide neurons to targets. Not yet identified ''healing'' factors found at the site of injury enhance regeneration and repair. Cell adhesion molecules show widespread activation outside the zone of injury and help direct neurons to targets. The glial cells themselves release trophic factors that help in recovery although they are also implicated in scar production, blocking neurons from recovery. 10 This brief overview of neural changes following brain damage and spontaneous recovery highlights some possible targets of pharmacological intervention for influencing brain repair. Research studies are being conducted to explore (1) replacement of neurotransmitters lost in cell death; (2) antagonizing toxic agents released in cell death; (3) decreasing excitotoxic substances; (4) enhancing calcium blockade; (5) introducing antioxidants; and (6) restoring normal circulation. Among these possibilities are scopolamine's effect in blocking the excitatory effects of acetylcholine, amphetamines mediated through dopamine to enhance epinephrine, norepinephrine, and serotonin, all of which have been shown to induce recovery, and antioxidants in the form of selegiline, vitamin E, Gingko biloba, and indocin. 10 All these options for pharmacological intervention remain, at present, in the experimental realm but provide exciting possibilities for future treatment of neurological deficits. In one model of recovery, neuroanatomy and neurochemistry overlap, linking distinct cognitive skills with site-specific neurotransmitters. This notion has led to the proposition of targeting focal brain lesions with pharmacological therapies. 11 Several neurotransmitters have been studied with regard to their effect on brain recovery in general; and there is also promising work looking at the pharmacological targeting of aphasia, in particular. What follows is a summary of this work including an overview of the catecholamines (dopamine, norepinephrine, amphetamines), acetylcholine, gammaaminobutyric acid (GABA), and serotonin.
NEUROCHEMISTRY AND PHARMACOTHERAPY OF SPEECH AND LANGUAGE DISORDERS

Catecholamines
DOPAMINE
Dopamine is a catecholamine, most familiar in the context of Parkinson's disease. Idiopathic Parkinson's disease is a neurodegenerative disorder producing its symptoms from the loss of the substantia nigra cells in the brain stem, responsible for producing dopamine. These symptoms include characteristic speech and language abnormalities. Studies of these patients provide evidence of dopamine's role in language function. 12 A review of nondemented Parkinson's patients by McNamara and Durso describes deficits in fluency, syntactic comprehension, and prefrontal attentional control, in addition to motor speech disorders. 12 They hypothesized that language disorders similar to those found in Broca's aphasia can occur with disruption of dopamine pathways between the basal ganglia and the prefrontal cortex in Parkinson's patients without concomitant dementia. They compared Parkinson's patients on and off levodopa (an exogenous source of dopamine that penetrates the blood-brain barrier), Broca's aphasics, and nonclinical control subjects. They found significant deficits in verbal fluency in patients with Parkinson's disease, showing improvement on and degradation off levodopa. 13 Dopamine pathways follow several anatomical configurations. One major pathway is the nigrostriatal pathway. This pathway originates in the pars compacta of the substantia nigra in the midbrain and projects to the striatum (caudate and putamen). 12, 14 The mesocortical pathway originates in the mesencephalic ventral tegmental area and projects to the striatum as well as to the amygdala, basal forebrain, and medial frontal lobes. 12 These medial frontal projections include the SMA which includes projections through the anterior cingulate, linking the midbrain with the frontal lobes. 12, 14 Dopaminergic activity was found to be greater in the left hemisphere compared with the right and in the dorsal areas compared with the lateral or medial areas in the frontal lobes. 12 These pathways are instrumental in controlling initiation and maintenance of complex motor activity, 12, 14 attentional switching, 12 and the production of sequential voluntary motor activity.
14 Lesions of the SMA have been shown to cause impairments in verbal fluency and initiation of output, which clinically can be classified as a transcortical motor aphasia. Albert and colleagues 15 described a patient with a transcortical motor aphasia resulting from a hemorrhagic infarct involving pathways from the SMA. They hypothesized that interrupted dopaminergic mesocortical projections caused decreased verbal fluency in this patient, and that by increasing dopamine to the brain they might improve this patient's verbal fluency. They specifically targeted speech hesitancies and impaired verbal initiation with the postsynaptic dopamine agonist bromocriptine. In this open-label trial, bromocriptine up to 30 mg/day was paired with traditional speech therapy (5 sessions per week for 2 ½ months as an inpatient, and 3 sessions per week for 5 months as an outpatient). The patient was evaluated before, during, and after intervention using the Boston Diagnostic Aphasia Evaluation. Results showed significant improvement in verbal fluency, with a decreased number of pauses, better naming, and fewer paraphasias within 10 days of treatment. This improvement was maintained throughout the period of treatment, but when retested 1 month after bromocriptine was discontinued, the patient had returned to or scored below baseline on the various speech and language measures. 15 This promising case study, published in 1988, led to further investigations of dopaminergic agents for the treatment of aphasia. Bromocriptine is the most widely studied of these pharmacological agents to date and reports are variable. In 1992, Sabe and coworkers 16 conducted an open-label trial of bromocriptine in nonfluent aphasia. They studied seven nonfluent patients with left frontal lesions who were at least 1 year poststroke. Bromocriptine was titrated to a maximum of 60 mg/day followed by a washout period. They found improved fluency in their subjects, which directly correlated with increasing dose. This improvement was most evident in the three patients classified as having moderate transcortical motor aphasia compared with four other patients (two patients with Broca's, one with global aphasia, and one with severe transcortical motor aphasia). Improvements disappeared when bromocriptine was discontinued. 16 In a subsequent study, Sabe and associates 17 looked at bromocriptine in seven patients with nonfluent aphasia using a randomized, double-blind placebo design. All subjects were classified as moderate in severity, had perisylvian lesions, and were at least 1 year postonset. Five subjects had experienced stroke and two had experienced closed head injuries. Again, bromocriptine was titrated to a maximum of 60 mg/day followed by a washout period. Speech measures were significant words (number of words with high semantic content), content units (total number of grammatical and semantic words), pauses greater than 3 seconds, controlled oral word association test for fluency, and naming. All patients received bromocriptine in the first arm of the study, followed by placebo, to control for a practice effect. No significant effects of the drug or placebo were found for any of the parameters measured. 17 In 1995, Gupta and associates 18 performed a similar study to that of Sabe et al using a double-blind, placebo-controlled, crossover design. Their subjects had nonfluent aphasia (seven with transcortical motor aphasia, four with Broca's aphasia, and nine with a mixed anterior aphasia) and received bromocriptine titrated to a maximum dose of 15 mg/day. Speech and language measurements were fluency (mean phrase length) and content (information index: total number of content words divided by the total number of function words). Like Sabe et al, they were unable to document a significant change in aphasia severity, speech fluency, or language content with bromocriptine or placebo.
In 2000 Gold and colleagues 19 attempted to separate qualitative from quantitative parameters in examining nonfluent aphasia patients in an open-label trial of bromocriptine. They examined four patients (two with transcortical aphasia and two with Broca's aphasia) treated with bromocriptine up to 15 mg/day. These investigators looked specifically at anomia in terms of a storage deficit (loss of word representation) and/or a retrieval deficit (loss of access to a word). They proposed that bromocriptine would improve word retrieval and increase speed of cognition. They did, in fact, demonstrate significantly improved scores, which returned to baseline following discontinuation of bromocriptine. The most dramatic improvement was seen in the patient with the most frontal damage disrupting the mesocortical dopaminergic pathways.
Dopaminergic projections appear to be involved in several important speech and language functions, including initiation, fluency, naming (especially lexical retrieval), and language content. It makes intuitive sense that potentiating dopaminergic availability would improve speech and language. Although bromocriptine showed some promise in the initial study of Albert and coworkers, 15 as well as in Gold and associates' more recent qualitative evaluation, 19 other studies have been less compelling. [16] [17] [18] Note, however, that the greatest number of subjects in any bromocriptine study is the 20 aphasic patients of Gupta and researchers.
An important consideration for these studies is that side effects can occur from dopaminergic agents; these most commonly include dizziness, drowsiness, and fainting. Less-common side effects are transient nausea, vomiting, and gastrointestinal upset. Almost a third of subjects show a decrease in systolic blood pressure at the onset of therapy, mostly asymptomatic. In at least one case, severe dystonia limited the usefulness of therapy. Some side effects are dose-dependent. The optimal dose has not been determined. A large-scale, well-designed, randomized, double-blind, placebo-controlled study has yet to be completed.
NOREPINEPHRINE
Norepinephrine is a catecholamine that originates in the locus ceruleus of the pons in the brainstem, and projects to the entire forebrain and primary sensory and motor cortex. Afferents to the locus ceruleus arise from the dorsolateral prefrontal cortex. Disruption of norepinephrine function will disturb prefrontal functions. 20 Norepinephrine levels decline after stroke in the cerebrum, brainstem, cerebellum, and cerebrospinal fluid. Drops in levels of norepinephrine are most evident ipsilateral to the side of the lesion. 21 The locus ceruleus is influenced by corticotropin-releasing factor, which in turn acts to release adrenocorticotropin. This hormone is secreted in excess in the stress response and has also been shown to be hypersecreted in depression. 22 Major depression has been found to be more common after left-hemisphere strokes, especially in those producing anterior lesions. 23 Agents that potentiate norepinephrine have been widely available for treatment of depression and may also improve overall recovery from brain damage. 24 Depression is a common comorbidity of stroke, estimated in 30 to 40% of patients. Finklestein and colleagues 24 found that treatment of depression improved functional outcome following stroke. In contrast, Lipsey and associates 25 found that nortriptyline, a commonly used tricyclic antidepressant that blocks reuptake of norepinephrine, effectively treated the depression but that neurologic function remained the same. Note that while depression is associated with focal left-hemisphere strokes and depletion of norepinephrine, it has not been correlated with severity of neurologic disability. 24 There is a high frequency of depression in patients with aphasia but no statistically significant correlation between the two. 26 
AMPHETAMINES
Amphetamines are potentiators of the sympathetic nervous system (sympathomimetics) and include methylphenidate (Ritalin), dextroamphetamine (Dexedrine), amphetamine, modafinil (Provigil), and pemoline (Cylert). They act to enhance the release of norepinephrine and block its reuptake, thereby potentiating its effect. 27 There is evidence for dextroamphetamine's role in promoting recovery after brain injury in the postacute phase. After induced strokes, animals have been evaluated for effects of dextroamphetamine on motor function, sensory-motor integration, and binocular depth perception. Enhanced neural sprouting and synaptogenesis were found with dextroamphetamine, and results were even more pronounced if treatment with dextroamphetamine was paired with practice. Amphetamines also have been shown to have a positive effect on stroke recovery by reversing the diffuse cortical depression of glucose metabolism. Damage to the locus ceruleus (the source of norepinephrine) potentiates this depression. Dextroamphetamine reverses this effect. 28 There may be some improvement in nonfluent aphasia with use of amphetamines. In one of the earliest studies on treatment of aphasia with dextroamphetamines, in 1970, Benson 29 looked at ten patients in a doubleblind, placebo-controlled study. Improvements in verbal and nonverbal domains were found in the early postonset group (2-3 months postonset) but not in the later postonset group (6 months postonset). More recently, WalkerBatson and others 27 studied 21 patients randomized to administration of either 10 mg of dextroamphetamine or placebo. Both groups also received ten 1-hour sessions of speech therapy. All subjects were 16 to 45 days postonset and had nonhemorrhagic strokes with moderate to severe aphasia. Results showed that the group receiving the active drug had an accelerated rate of aphasia recovery. This is a promising finding, although the study used small groups of subjects and administered drug therapy during an active period of spontaneous recovery. The results of another study with amphetamines was less impressive. Methylphenidate and chlordiazepoxide (a benzodiazepine) were compared in a double-blind, placebo-controlled, crossover study. No significant difference in language function in any group was demonstrated. 28 Acetylcholine Acetylcholine is found in most places in the nervous system. Primary sources include the nucleus basalis of Meynert and the substantia inominata, two cerebral nuclei at the base of the forebrain. There is evidence, however, that cholinergic activity may be greater in the left hemisphere than in the right, especially in the temporal lobe. The left temporal lobe is an area important for verbal memory; therefore, the finding that cholinergic activity may be more prominent in the left temporal lobe suggests that verbal memory may be mediated by acetylcholine. 11 This observation may also represent a neurochemical underpinning for cerebral dominance for language. These basal forebrain nuclei project throughout the cortex but receive input more selectively from the reticular activating system, limbic system, and orbitofrontal cortex. Nuclei from the medial septum and diagonal band project to the hippocampus, cingulate, and hypothalamus. 20 Anticholinergic agents, such as scopolamine, have been shown to impair verbal memory skills of storage, retrieval, and working memory. A study by Mimura and associates looked at patients on tricyclic antidepressants, which have significant anticholinergic effects. The drug produced speech blockage, suggesting suppression of verbal fluency. Naming and comprehension of language may depend on verbal memory; theoretically, therefore, posterior fluent aphasias may respond to augmentation of acetylcholine function.
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In 1970 Luria 30 looked at the effect of galanthamine (an anticholinesterase agent which blocks the breakdown of acetylcholine) on cognitive function. He noted improvements in articulation, paraphasias, naming, comprehension, and fluency. In a later study, however, no effect was found on language function for another anticholinesterase inhibitor, neostigmine, perhaps because of less penetration into the central nervous system. 31 However, another anticholinesterase inhibitor, ameridin, was found to be beneficial in eight patients with semantic aphasia. 31 Compared with a control group, patients treated with ameridin demonstrated improvement in naming and comprehension. Physostigmine, an anticholinesterase inhibitor, administered to one patient with fluent aphasia also showed improved naming and comprehension.
There is some evidence that acetylcholine has a neuroprotective effect during ischemic hypoxia and that 5-citidine diphosphocholine (CDP-choline or citicoline) started within 24 hours of onset can increase rate of recovery, increase function, and increase Mini-Mental State Examination scores in patients undergoing acute ischemic stroke. 32 This improvement is thought to occur by provision of substrate (choline and citidine) to synthesize phosphatidylcholine, which is important for cell membranes and for production of acetylcholine. CDP-choline also acts to incorporate free fatty acids into the cell membrane to prevent degradation. 33 CDP-choline has not yet been studied specifically in patients with aphasia.
The use of piracetam, a gamma aminobutyric acid derivative, has been studied by Huber and Willmes 34 in German patients with aphasia. Piracetam has a direct cholinergic effect via release of acetylcholine. It has been suggested to increase neuronal membrane fluidity for improved neurotransmission, which in turn provides cell protection from hypoxia by enhancing cellular metabolism, and to improve neuronal activity by its multiple effects on microcirculation, including the decrease of platelet aggregation, increase of red blood cell deformability, and reduction of capillary wall vasospasm. The result of infusions of piracetam is a reduction in plasma and whole blood viscosity, thereby improving cerebral blood flow and cerebral perfusion. In their doubleblind placebo controlled pilot study, Huber and colleagues 34 administered either placebo or piracetam and ten 60-minute sessions of speech therapy to 50 patients over the course of 6 weeks. There was significant reduction in overall aphasia severity, especially in written language. Improvement was more significant in those patients with Wernicke's or Broca's aphasia, compared with those with global aphasia. In a subsequent study of piracetam, Kessler and colleagues 35 used PET scan during word repetition tasks, language assessment, and neuropsychological testing. They found improvement in cerebral blood flow in language areas, most significantly in Heschl's gyrus, superior temporal gyrus (Wernicke's area), and frontal area corresponding to Broca's area. Speech and language improved as well. Since patients were enrolled within 14 days of stroke onset, however, effects of spontaneous recovery cannot be ruled out. Tanaka and coworkers 36 studied the direct cholinergic effects on language in aphasia using bifemelane 300 mg/day compared with placebo. Four patients with left temporal lobe lesions 6 to 8 weeks postonset were studied. The two patients receiving active drug therapy plus speech therapy showed greater improvement in auditory comprehension, animal naming, and confrontation naming than the two patients receiving speech therapy alone.
In 2001, Tanaka and Albert 37 reported on the effects of another centrally active cholinergic agent, aniracetam, in eight patients with Wernicke's aphasia. A double-blind crossover design with nilvadipine, a calcium channel blocker (thought to increase cerebral blood flow), was used. Improvements on the Boston Naming Test, Action Naming Test, Word Generation Test for Categories, and tests of perseveration were seen in the group treated with aniracetam, but not in the group treated with nilvadipine. These results again support the possible benefit of of cholergenic agents for treatment of aphasia.
Indirect effects of language function on acetylcholine manipulation, using acetylcholinesterase inhibitors, also have been studied in cases of Alzheimer's disease. Looking at naming in the context of verbal memory linked to lexical semantics in patients with Alzheimer's disease, researchers postulated that cholinergic input would benefit those with a posterior fluent aphasia. The hypothesis was derived from the evidence of worsening verbal memory in patients given scopolamine, an anticholinergic agent. Additionally, markers for cholinergic activity, including choline acetyltransferase, have been found to be higher in the left hemisphere compared with the right, and in particular in the left superior temporal gyrus language area.
14 Donepezil is a centrally acting, selective, reversible anticholinesterase inhibitor currently approved for use in the treatment of mild to moderate Alzheimer's disease. Berthier and coworkers 38 conducted an open-label trial using donepezil to treat chronic aphasics poststroke. Eleven patients were evaluated over 20 weeks with 5 mg for 4 weeks, then 10 mg for 12 weeks, followed by a 4-week washout period. Improvement was documented on tasks of phonemic discrimination of nonwords, repetition of words and nonwords, word-picture matching, naming, ''global aphasia severity rating,'' and tests of input and output phonology and lexical semantic processing. These findings are in agreement with findings from earlier studies (of eight patients with semantic aphasia 14 and four patients with fluent aphasia 36 ) showing improvement in naming and auditory comprehension after treatment with an anticholinesterase agent. Although preliminary and experimental, these findings are promising, as the various anticholinesterase medications, galantamine and rivastigmine in addition to donepezil, are already widely used and well tolerated in the treatment of Alzheimer's disease. Thus, the possibility that these drugs may be useful in aphasia must be seriously considered.
Gamma-aminobutyric Acid
GABA is an excitatory neurotransmitter, acting to inhibit neurotransmitters in all areas of the brain. It interacts closely with glutamate, norepinephrine, and acetylcholine. GABA agonists, typically in the form of benzodiazepines, are often used clinically to treat agitation, seizures, spasticity, and insomnia. 38 Diazepam, in particular, has been shown to disrupt and delay recovery of function following brain damage by preventing reactivation of subcortical regions distant from the lesion, interfering with release from diaschisis. 40 The drug has also been shown to enhance degeneration, encouraging cell death. 41 Sodium amytal, another GABA agonist, has been studied specifically for its potential efficacy in treating aphasia. Walker-Batson 42 summarizes the results of studies using sodium amytal to treat aphasia. In one of the earliest modern attempts to treat aphasia pharmacologically, sodium amytal was administered intravenously to two patients who had aphasia caused by traumatic brain injury. One showed improvement in language; the other patient also improved, but returned to baseline when the drug was withdrawn. This early attempt to treat aphasia pharmacologically with sodium amytal was followed in 1951 with 27 patients with traumatic brain injury, but no significant difference in language function was found in the treated group. Many years later in the mid1970s, another benzodiazepine was evaluated in the treatment of aphasia. Chlordiazepoxide was compared with methylphenidate and placebo in a double-blind, crossover study, but again no effect was found.
Serotonin
Serotonin is another central neurotransmitter that can be manipulated by various medications, whether through selective reuptake inhibiters like fluoxetine (Prozac), sertraline (Zoloft), or paroxetine (Paxil) or through 5HTA serotonin receptor agonists, like buspirone (Busbar) or trazodone (Desyrel). Decreased levels of serotonin have been demonstrated in depression. Reading and Orto 43 evaluated rehabilitation outcomes in depressed patients treated with trazodone compared with placebo using the Barthel Activities of Daily Living score. The treatment group showed consistent improvement, thought to be on the basis of increased activation, motivation, and participation. Since poststroke depression has been linked to left frontal lesions and nonfluent aphasia, pharmacological treatment of depression may result in improvement of aphasia.
In this context, Tanaka and Albert 44 looked directly at the effect of the selective serotonin reuptake inhibitor fluvoxamine maleate on aphasia. Ten patients with aphasia were evaluated with modified versions of the Western Aphasia Battery, Boston Naming Test, Action Naming Test, Token Test, parts of the Boston Diagnostic Aphasia Examination, Word Generation to FAS, category fluency tests, tests of perseveration, and articulatory agility. Other domains were evaluated with the Wechsler Memory Scale, tests of pointing span and hidden objects. They found improvements in mood and naming, particularly in the patients with fluent aphasia. They postulated this improvement to be on the basis of decreased depression and decreased perseveration. 44 Thus, antidepressants may enhance functional gains in language poststroke, and selective serotonin reuptake inhibitors may be the antidepressants of choice for this group of patients.
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SUMMARY: PHARMACOTHERAPY FOR APHASIA Research studies have been looking at the possibility of manipulating brain chemistry for functional gain in patients with aphasia, but, to date, no overwhelming evidence has emerged to support routine use of drugs as either a complementary or alternative treatment for aphasia. Studies have been largely anecdotal with small numbers of patients and varying types of aphasia. Improvements due to spontaneous recovery have been difficult to separate from treatment benefits. What emerges most clearly from a review of drug therapy for aphasia is the promising evidence that certain types of aphasia in certain patients in certain situations can improve with pharmacotherapy. The issue still to be determined by rigorous research is which types of aphasia in which patients and in which situations.
Catecholamines seem especially promising for nonfluent aphasias. Dopamine agonists, in particular bromocriptine, improve verbal fluency in transcortical motor aphasia. Norepinephrine affects prefrontal functions and seems to relieve symptoms of depression and improve overall recovery of function, including language, following stroke. Amphetamines potentiate norepinephrine to promote general recovery, and have been shown to improve language performance in some patients with nonfluent aphasia.
Acetylcholine is another major neurotransmitter being actively investigated. Direct acetylcholine treatment (ameridin, bifemelane, aniracetam) seems to offer hope for improving naming and comprehension in posterior aphasia. Anticholinesterase inhibitors (donepezil, galanthamine) have been shown to improve naming, auditory comprehension, and verbal memory in individuals with fluent aphasia.
GABA shows mixed effects, causing both delayed recovery after brain damage and improvements in aphasia, perhaps due to improved attention. Serotonergic agents (SSRIs) via selective serotonin reuptake blockade or through direct receptor agonists improve poststroke symptoms of depression, enhancing activation, motivation, and participation, which in turn improves rehabilitation outcome. Both fluent and nonfluent aphasia patients show improved mood and naming with concomitant reduction of both depression and perseveration.
The sometimes-positive results of studies on the pharmacotherapy of aphasia underscore the critical need for well-designed, randomized, well-controlled, clinical research studies. Such studies must look at specific outcomes, efficacy, doses, and chemical formulations, with numbers of subjects great enough to support treatment protocols that can complement current speech and language therapy approaches.
